NASDAQ$CLPT

ClearPoint Neuro Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Reported record revenues despite COVID-19 related challenges.

ClearPoint Neuro reported a revenue of $3.7 million for the fourth quarter of 2020, compared to $3.2 million for the same period in 2019. The company is optimistic about returning to pre-COVID procedure volume in the second half of 2021.

  • Total revenues were approximately $3.7 million, up from $3.2 million year-over-year.
  • Functional neurosurgery navigation and therapy product and service revenues decreased 5% year-over-year.
  • Biologics and drug delivery revenue increased 40% year-over-year.
  • Capital equipment product and related service revenue increased 41% year-over-year.

Headline financials

Total Revenue

$3.72M

Previous: $3.21M+15.7%
EPS (adj)

-$0.09

Previous: -$0.11+18.2%
Cash & Equivalents

$20.1M

No prior period

Revenue & EPS history

ClearPoint Neuro · Revenue · Quarterly

$3.72M

Q4 2020+15.7%vs Q4 2019
Beat estimate in 5 of 6 quarters(83%)
ActualEstimate

Revenue by segment

ClearPoint Neuro · $600K total across 1 segment · Q4 2020

  • Capital Equipment and Software
    $600K+34.5%

Forward guidance

ClearPoint Neuro is cautiously optimistic about the future, expecting a return to pre-COVID procedure volume in the second half of 2021.

Tailwinds

  • Hospitals are starting to schedule patients for March and April.
  • Expectation to return to pre-COVID procedure volume in the second half of 2021.
  • Strong balance sheet.
  • Stronger position than they started.
  • Talented team.

Headwinds

  • Closures and postponements related to ICU bed capacity due to the COVID-19 pandemic.
  • Not yet in a position to give a forecast for 2021.
  • Continuing effects of the COVID-19 pandemic.
  • Elective surgical procedures have not yet reached pre-pandemic activity.
  • COVID-related closures and postponements.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-1.7%

Avg return

Earnings day

-1.7%

Avg return

5 days after

-2.3%

Avg return

30 days after

34%

15 / 44 earnings

Positive

+35.8%

Q2 2024

Best reaction

-24.1%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.9%-12.1%+6.9%
Q4 2025-14.5%-14.8%+5.6%
Q3 2025-13.5%-8.3%-25.7%
Q1 2025-11.7%-7.6%-18.7%
Q4 2024-17.5%-22.1%-30.5%
Q3 2024-12.9%-16.9%+0.7%
Q2 2024+35.8%+46.6%+78.3%
Q1 2024+0.8%-1.3%-3.4%
Q4 2023+18.9%+18.6%+2.8%
Q3 2023-24.1%-14.3%+13.9%
Q2 2023-5.0%-8.9%-20.2%
Q1 2023-7.0%-8.8%-28.2%
Q4 2022-3.3%-4.5%-0.5%
Q3 2022-3.5%+2.6%-6.9%
Q2 2022+10.3%+9.6%-14.3%
Q1 2022+1.0%+17.0%+49.0%
Q4 2021-0.1%+6.2%+19.0%
Q3 2021-8.3%-11.3%-35.1%
Q2 2021-17.6%-20.2%-13.2%
Q1 2021+3.2%+4.5%+15.7%
Q4 2020-22.8%-14.0%-3.9%
Q3 2020+13.3%+25.3%+52.9%
Q2 2020-2.2%+5.3%+12.2%
Q1 2020-12.4%-14.9%+7.2%
Q4 2019+18.8%+13.6%-16.3%
Q3 2019-0.7%+2.3%+5.4%
Q2 2019+5.8%-1.2%-1.0%
Q1 2019+7.4%+10.6%+16.2%
Q4 2018-3.1%-3.1%-8.3%
Q3 2018-2.4%-4.9%-14.6%
Q2 2018-2.2%-6.6%-20.9%
Q1 2018-5.6%-7.4%-22.6%
Q3 2017+1.5%-8.0%-0.4%
Q2 2017-0.5%+8.4%+1.1%
Q1 2017+0.0%-3.9%-43.0%
Q3 2016+17.9%-3.8%-23.1%
Q2 2016-5.9%-15.3%-20.7%
Q2 2015-11.3%
Q1 2015-5.6%
Q2 2014+0.0%
Q1 2014+2.4%
Q2 2012+1.7%
Q1 2013-0.8%
Q3 2012+3.3%
Q1 2012
Q4 2011
Q3 2011
Q2 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro